Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735449 · ClinicalTrials.gov registry record · Phase 4
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 204
- Enrollment target
NCT00735449: Completed Phase 4 study, sponsored by Allergan.
NCT00735449 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 204 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00735449, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 204 participants
- Enrollment target
Study Summary
Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.
Primary Outcome
Mean IOP at 10 AM at week 12. IOP is a measurement of the fluid pressure in the eye.
Interventions
- DRUG latanoprost 0.005%
- DRUG Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%
- DRUG timolol maleate 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
What the finished NCT00735449 record still lists
NCT00735449 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 3 interventions - of which latanoprost 0.005% is the first listed.
NCT00735449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00735449 about?
NCT00735449 is a clinical study titled "Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects". Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.
What is the current status of trial NCT00735449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 204 participants. The study started on 2008-07. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00735449?
The interventions under investigation include: latanoprost 0.005% (DRUG), Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% (DRUG), timolol maleate 0.5% (DRUG).
Who is sponsoring clinical trial NCT00735449?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00735449's enrollment target sits among peer trials
204 402nd of 2000 higher than 1,598 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia